Injective (INJ) is currently priced at $3.64, reflecting a notable 6.46% increase over the past 24 hours. The daily trading range has been between $3.41 and $3.68, indicating healthy volatility and interest in the asset.

The trading volume stands at approximately $59.91 million, with a volume-to-market cap ratio of 16.47%, which suggests strong trading activity relative to its market capitalization. Short-term moving averages are bullish, with the 8 SMA at $3.61 showing a 0.92% increase, while longer-term SMAs also demonstrate positive trends, particularly the 55 SMA at $3.48, up 4.45%.

The 1-hour RSI is at 72, signaling that INJ may be overbought in the short term, which could lead to a pullback. Conversely, the 7-day RSI at 52 indicates that the asset is neither overbought nor oversold, suggesting potential for further upside.

The price has increased by approximately 25.91% over the last 30 days, reflecting strong bullish momentum and investor confidence. The all-time high of $52.62 reached in March 2024 indicates substantial growth potential, although the current price represents a significant retracement from that level.

Given the current price action, moving averages, and RSI indicators, the market sentiment for Injective appears bullish in the medium term. However, the high hourly RSI suggests a short-term consolidation or correction may be imminent.

In conclusion, the recommendation for Injective (INJ) is to Hold. The asset shows strong momentum and potential for future growth, but short-term overbought conditions warrant caution against new entries at this level.